NCT05653063Active, not recruiting
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams. The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1029 (actual)
- First submitted
- 3 Nov 2022
- Start date
- 7 Dec 2023
- Primary completion date
- 16 Jan 2026
- Lead sponsor
- University College, London
- NCT number
- NCT05653063
What you commit to
- Study type: Observational
- Participants enrolled: 1029
- From 7 Dec 2023 to the primary completion date, 16 Jan 2026
- 6 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible.
- Patients receiving palliative radiotherapy
Age
- Patients aged \< 18years.
Who the study is looking for
- Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy.
- Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy.
- Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy.
- Mental capacity to understand and consent to participate in the study.
- Patients aged ≥18years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| TATA Medical Centre Coordinator of this site? Confirm its status | Kolkata | India | Unknown status |
| Tata Memorial Hospital Coordinator of this site? Confirm its status | Mumbai | India | Unknown status |
| King Hussein Cancer Center Coordinator of this site? Confirm its status | Amman | Jordan | Unknown status |
| University of Malaya Medical Center Coordinator of this site? Confirm its status | Kuala Lumpur | Malaysia | Unknown status |
| Groote Schuur Hospital Coordinator of this site? Confirm its status | Cape Town | South Africa | Unknown status |
| Tygerberg Hospital Coordinator of this site? Confirm its status | Stellenbosch | South Africa | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.